Day: December 29, 2020

● Patent supporting Autosomal Dominant PolycysticKidney Disease Granted – XRx-008 Program ●CALGARY, Alberta, Dec. 29, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce receipt of notification that the patent “Formulations of Xanthine Oxidase Inhibitors” will be granted by the European Patent Office. The patent covers compositions and methods of using XORTX’s proprietary formulations of xanthine oxidase for, renal and other diseases where aberrant purine metabolism has been implicated in disease progression.Dr. Allen Davidoff, CEO of XORTX stated, “This newly granted patent, covers compositions of formulations key to XORTX’s platform technology...

Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into Europe TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer into Europe, where the first patient has now been enrolled. The study continues to actively recruit patients in the U.S. and Israel, with over 200 patients enrolled to date.“VB-111 is our proprietary anti-cancer gene therapy product candidate that has shown overall survival benefit across multiple tumor types,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “We are pleased to expand the OVAL potential registration study of VB-111 in patients...

HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with Mexican pharmaceutical company Innovare R&D to expand its ongoing clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 in Mexico. The Phase II study in Mexico is subject to the approval of local authorities, with the goal of being conducted under the U.S. Food and Drug Administration (FDA) cleared protocol.In accordance with the agreement, Innovare will open clinical sites and enroll patients for the proposed clinical study in Mexico. Innovare will fund the study in Mexico and will purchase...

LA JOLLA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS).Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.  The allowed claims cover a method of (i) alleviating the negative effects of progressive multiple sclerosis, (ii) treating progressive multiple sclerosis, or (iii) slowing the progression of progressive multiple sclerosis by administering...

Valoe Corporation                     Stock Exchange Release          29 December 2020 at 13.30 Finnish timeIn 2021, Valoe Corporation (“Company”) will publish an annual report, a financial statements release, a half-year financial report and two business reviews. Previously, the Company has published a financial statements release and three interim reports, but in the future, the Company will disclose a shorter business review for the first and third quarters of a financial year.The schedule of the financial reports is as follows:–          Financial statements release 2020 on Wednesday 24 February 2021–          Business review for January-March 2021 on Tuesday 18 May 2021–          Half year report for January-June 2021 on Wednesday 25 August 2021–          Business review for January-September 2021 on Wednesday...

Valoe Oyj                                                                   Pörssitiedote 29.12.2020 klo 13.30                                                                                                                                                         Valoe Oyj (”Yhtiö”) julkistaa vuoden 2021 aikana vuosikertomuksen, tilinpäätöstiedotteen, puolivuosikatsauksen sekä kaksi liiketoimintakatsausta. Aiemmin yhtiö on julkistanut tilinpäätöstiedotteen lisäksi kolme osavuosikatsausta, mutta jatkossa yhtiö julkistaa tilikauden kolmelta (Q1) ja yhdeksältä kuukaudelta (Q3) lyhyemmän taloudellisen katsauksen.Taloudellisten tiedotteiden aikataulu on seuraava:– Tilinpäätöstiedote 2020 keskiviikkona 24.2.2021– Liiketoimintakatsaus tammi-maaliskuu 2021 tiistaina 18.5.2021– Puolivuosikatsaus tammi-kesäkuu 2021 keskiviikkona...

PRESS RELEASE – REGULATED INFORMATIONNotification of transactions in shares by persons discharging managerial responsibility (“PDMRs”)Cambridge (UK) 29 December 2020: The Company makes the following announcement and notifications in respect of the EU Market Abuse Regulation.About Global GraphicsThrough its operating subsidiaries, Global Graphics PLC (Euronext Brussels: GLOG) is a leading developer of integrated hardware and software solutions for graphics and industrial inkjet printing. Customers include press manufacturers such as HP, Canon, Durst, Roland, Hymmen and Mark Andy.  Global Graphics PLC is headquartered in Cambridge UK.  Its subsidiary companies are printing software developers Global Graphics Software; the industrial printhead driver solutions specialists, Meteor Inkjet; and the pre-press software specialists...

SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”, or the “Company”), announced that its Joint Venture, GBT Tokenize Corp (“GBT/Tokenize”), is developing a new security protocol, code name qNET, for its qTerm vital device.As qTerm device will be communicating through a mobile application with a backend program, transferring private information, a secured network protocol is needed to set the rules and conventions for communication between the network devices. The protocol includes methods for node’s identification, packet exchange and formatting rules. GBT is developing a highly secured protocol based on its database sharing technology. In this method, a communication message is done using a packet’s segmentation technique. The segments are sent to many nodes as an index...

Launching Rubicon Organics’ third brand, 1964™ exclusive to QuebecProduct innovation portfolio continues to expand with the launch of hashVANCOUVER, British Columbia, Dec. 29, 2020 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified cannabis, today announced that it has received its first purchase order from the Société québécoise du cannabis (“SQDC”) under the letter of understanding that was announced on November 24, 2020.Rubicon Organics is launching the 1964™ brand exclusively for Quebec. The 1964™ brand will include both flower and hash. The Company’s product portfolio in Quebec will include dry flower and pre-rolls sold under the Simply Bare™ Organic brand and flower and hash sold under the 1964™...

Lancement de la troisième marque de Rubicon Organics, 1964™ exclusive au QuébecLe portefeuille d’innovations continue de s’étendre avec le lancement du haschichVANCOUVER, Colombie-Britannique, 29 déc. 2020 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” ou la “Société”), un producteur autorisé axé sur la culture et la vente de cannabis certifié biologique, a annoncé aujourd’hui avoir reçu sa première commande de la Société québécoise du cannabis («SQDC») en vertu de la lettre d’entente annoncée le 24 novembre 2020.Rubicon Organics lance la marque 1964™ exclusivement pour le Québec. La marque 1964™ comprendra à la fois des fleurs séchées et du haschich. Le portefeuille de produits de la compagnie au Québec comprendra aussi des fleurs séchées et des pré-roulés vendus sous la marque...